Findings demonstrate that exosomal mir-30a-5p targets Calm1 to reduce complications in diabetes mellitus, suggesting therapeutic potential.
NSMC-EXO-derived miR-30a-5p protects against DMED by directly targeting Calm1 and attenuating pro-apoptotic and pro-fibrotic signaling. These findings provide mechanistic insight supporting the development of exosome-based therapeutic approaches for DMED.
No takes yet. Share an insight, caveat, or question.
Song et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: